Our core content on Lung conditions and related factsheets has been translated to a number of other languages.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
Our core content on Lung conditions and related factsheets has been translated to a number of other languages by our volunteer team.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
Vagn Jespersen (Danish Lung Cancer Association and ELF lung cancer patient advisory group) attended a workshop on the challenges of approving anti-cancer immunotherapeutic drugs on 4–5 February, 2016 in London.
The workshop was organised by the European Medicines Agency and the Cancer Drug Development Forum and was a mix of keynote speakers, panel discussions and a networking dinner. Immunotherapy drugs have brought important advances in patient care and have considerably changed the landscape of treatment options for people with melanoma and lung cancer. However there are still many challenges on how to bring these treatments through regulatory approval and into clinical practice.
Discussions included the challenges of combining immunotherapies with targeted therapies, developing novel immune–oncology combinations, biomarkers, and evaluating effectiveness, including patient reported outcomes and patient perspectives.
Of 120 participants, Vagn was the only patient among leading doctors, scientists, European regulators and representatives from the industry in Europe and the USA, and was able to contribute to discussions and highlight some of the ethical issues that may arise in clinical trials.
Sign up to our free monthly newsletter to get the latest information and research news on lung conditions, plus views from experts and patients! You can unsubscribe at any time.
ELF is a non-profit organisation registered as a UK company (VAT no. GB 115 0027 74) and charity (no. 1118930).
Our Brussels office enterprise number is 0738.383.695
European Lung Foundation's TR ID number in the Transparency Register is: 094039644810-79
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
No description
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.